Adult stem/progenitor cells are present in many organs and tissues, e.g., fat , bone marrow, teeth, heart, gut, kidney and liver, and remain quiescent for long period of time until activated by a disease or injury trigger. In many cases of disease/injury, these tissues are maintained and repaired by the tissue-specific stem cells, which typically generate the cell types of the tissue in which they reside.
ADULT STEM CELLS are :
- NOT embryonic or fetal stem cells
- Collected with no harm to the donor
- Proven to be effective in a multitude of diseases
Are Stem Cells Safe?
A paper published in 2012 which analyzed 1012 people treated with Mesenchymal Stem Cells (MSCs) found that MSC treatment was safe and called for further study. (Click Here to View Paper – .pdf)
2016 study. Type 2 Diabetes. 31 in treatment group. No serious adverse reactions, including fever, chills, liver damage, hypersensitivity, infection, hemorrhage, proteinuria, myocardial infarction, venous thromboembolic events or other arterial thromboembolic events, were detected following WJ‑MSC infusion in any of the patients who completed the study protocol, and no chronic side effects or lingering effects were detected during the follow‑up. (View Full Article – pdf)
2013 study of MSCs for rheumatoid arthritis 86 subjects treated (172 in study). “No serious adverse effects were observed during or after infusion.” Conclusion “treatment with DMARDs plus UC-MSCs may provide safe, significant, and persistent clinical benefits for patients with active RA”
2016 Single patient. There were no complications related to transplantations and no side effects related to the therapy during 2 years of treatment. (View Abstract)
Are Stem Cells Effective?
Diabetes type 2 was effectively treated after two IV treatments with umbilical cord MSCs. Three year follow up, gold standard, double blind placebo controlled study “Long term effect and safety of Wharton’s jelly-derived mesenchymal stem cells on type 2 diabetes.” (View Abstract) (View Complete Paper – pdf)
Juvenile rheumatoid arthritis was successfully treated using umbilical cord MSCs. Disease symptoms were reduced and markers of the disease decreased significantly. 2016 study of 10 patients. (View Abstract) (View Complete Paper – pdf)
Rheumatoid Arthritis (RA) – 172 patient trial, treated with combination of standard medications and umbilical cord MSCs. No adverse events during or after treatment. Study conclusion: “Treatment with DMARDs plus UC-MSCs may provide safe, significant, and persistent clinical benefits for patients with active RA.” (View Abstract)
2014 review paper of MSCs to treat acute organ injury. Promising preclinical evidence has resulted in several phase I, phase II and phase III clinical trials that are currently still in progress and will further determine the optimal clinical use of MSCs in the treatment of organ injury. (View Complete Paper – pdf)
Continuous improvement after multiple mesenchymal stem cell transplantations in a patient with complete spinal cord injury. (View Abstract)
Results of a Phase I/IIa Clinical Trial for the treatment of amyotrophic lateral sclerosis (ALS, or “Lou Gehrig’s disease”) with autologous bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) yielded further evidence for the safety and efficacy of BM-MSCs in slowing the progression of ALS by providing anti-inflammatory neurotrophic support to spinal motoneurons. (View Abstract) (View Complete Paper – pdf)
What do the experts say?
“The cell based therapies being proposed and tested clinically and investigator initiated trials are curative.” – Arnold Caplan, PhD – Case Western Reserve University
Dr. Caplan is widely hailed as the “father of the mesenchymal stem cell”. His comments were given at the FDA/CBER meeting for Draft Guidances Relating to the Regulation of Human Cells, Tissues or Cellular or Tissue-Based Products in September, 2016.
Public Hearing before FDA/CBER (Food and Drug Administration/ Center for Biologics Evaluation and Research), “Draft Guidances Relating to the Regulation of Human Cells, Tissues, or Cellular or Tissue-Based Products,” 12 September 2016: (View Full Transcript)